medigraphic.com

2006, Número S4

<< Anterior Siguiente >>

Arch Cardiol Mex 2006; 76 (S4)


Bases moleculares de la insuficiencia cardíaca

Rodríguez PJM, Gallardo GJ, Vargas AG

Idioma: Español
Referencias bibliográficas: 44
Paginas: 10-17
Archivo PDF: 135.41 Kb.


RESUMEN

La insuficiencia cardíaca (IC) es un estado fisiopatológico complejo en el cual el corazón es incapaz de bombear sangre con la frecuencia necesaria para cubrir los requerimientos de los tejidos. La IC se origina generalmente cuando existen antecedentes de enfermedad cardiovascular como pueden ser la aterosclerosis, la cardiomiopatía, la miocarditis, las malformaciones congénitas y las alteraciones valvulares. Recientemente se han hecho progresos importantes para entender la etiología, la patogénesis y los mecanismos implicados en la IC. Varios mecanismos relacionados tales como el estrés oxidativo, las señales de traducción, las alteraciones en el manejo del calcio intracelular, la disfunción mitocondrial y la presencia de mutaciones han sido propuestos como disparadores de la insuficiencia cardíaca.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hunt SA, Backer DW, Chin ML, Cinquegrani MP, Feldman AM, Francis GS et al: Report of the ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. Circulation 2001; 104: 2996-3007.

  2. Zipes DP, Libby P, Bonow RO, Braunwald E: En: Braunwald´s Heart Disease: A Textbook of Cardiovascular Medicine. Chapter 21. Pathophysiology of Heart Failure. USA, 7th edition. 2005: 509-538.

  3. Young JB: The Global Epidemiology of Heart Failure. Med Clin N Am 2004; 88: 1135-1143.

  4. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, DAgostino RB, Kannel WB, et al: Framingham Heart Study: Lifetime Risk of Congestive Heart Failure. Circulation 2002; 106: 3068-3072.

  5. Benjamin IJ, Schneider MD: Learning from failure: congestive heart failure in the postgenomic age. J Clin Invest 2005; 115: 495-499.

  6. Francis GC: Pathophysiology of chronic heart failure. Am J Med 2001; 110: 37S-46S.

  7. Rayment NB, Haven AJ, Madden B, Murday A, Trickey R, Shipley M, et al: Myocyte loss in chronic heart failure. J Pathol 1999; 188: 213-219.

  8. West JB: Cardiac energetics and myocardial oxygen consumption. Physiologic Basis of Medical Practice. Williams and Wilkins. Baltimore, Maryland, USA. 1991: 250-260.

  9. Kourie JI: Interaction of reactive oxygen species with ion transport mechanisms. Am J Physiol 1998; 275: C1-24.

  10. Huang Y, Hickey RP, Yeh JL, Liu D, Dadak A, Young LH, et al: Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy, availability, calcium flux, and contractility in the normoxic heart. FASEB J 2004; 18: 1138-1140.

  11. Davis KJ: Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 1995; 61: 1-31.

  12. Rathore N, John S, Kale M, Bhatnagar D: Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol Res 1998; 38: 297-303.

  13. Lockwood TD: Redox control of protein degradation. Antioxid Redox Signal 2000; 2: 851-878.

  14. Rahman I: Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung disease. J Biochem Mol Biol 2003; 36: 95-109.

  15. Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM: Risk factors for heart failure in the elderly: A prospective community based study. Am J Med 1999; 106: 605-612.

  16. McCord JM, Fridovitch I: The reduction of cytochrome C by milk xanthine oxidase. J Biol Chem 1968; 243: 5753-5760.

  17. McCord JM, Fridovitch I: Superoxide dismutase. An enzymatic function for erythrocuprein (homocuprein). J Biol Chem 1969; 244: 6049-6055.

  18. Sabri A, Hughie HH, Luchéis PA: Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003; 5: 731-740.

  19. Izumiya Y, Kim S, Izumi Y, Yoshida K, Yoshiyama M, Matsuzawa A, et al: Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res 2003; 93: 874-883.

  20. Giordano FJ: Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-508.

  21. Kaplan P, Babusikova E, Lehotsky J, Dobrota D: Free radical-induced protein modification and inhibition of Ca2+ -ATPase of cardiac sarcoplasmic reticulum. Mol Cell Biochem 2003; 248: 41-47.

  22. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS: Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-388.

  23. Bonaventura J, Gow A: NO and superoxide: opposite ends of the seesaw in cardiac contractility. Proc Natl Acad Sci USA 2004; 101: 16403-16404.

  24. Hare JM: Nitroso-redox balance in the cardiovascular system. N Engl J Med 2004; 351: 2112-2114.

  25. Hare JM, Stamler JS: NO/redox disequilibrium in the failure heart and cardiovascular system. J Clin Invest 2005; 115; 509-517.

  26. Dorn GW, Force T: Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115: 527-537.

  27. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A: Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.

  28. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, et al: Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002; 110: 737-749.

  29. Schwartzbauer G, Robbins J: The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem 2001; 276: 35786-35793.

  30. Nurese K, King GL: Protein kinase C and myocardial biology and function. Circ Res 2000; 86: 1104-1106.

  31. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, et al: PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004; 10: 248-254.

  32. Yano M, Ikeda Y, Matsuzaki M: Altered intracellular Ca2+ handling in heart failure. J Clin Invest 2005; 115: 556-564.

  33. Fabiato A: Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 1983; 245: C1-C14.

  34. Bers DM: Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.

  35. Hasenfuss G: Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 1998; 37: 279-289.

  36. Hasenfuss G, Pieske B: Calcium cycling in congestive heart failure. J Mol Cell Cardiol 2002; 34: 951-969.

  37. Okuda S, Yano M, Doi M, Oda T, Tokuhisa T, Kohno M, et al: Valsartan restores sacroplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure. Circulation 2004; 109: 911-919.

  38. Huss JM, Kelly DP: Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 2005; 115: 547-555.

  39. Stanley WC, Chandler MP: Energy metabolism in the normal and failure heart: potential for therapeutic interventions. Heart Fail Rev 2002; 7: 115-130.

  40. Bishop SP, Altschuld RA: Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 1970; 218: 153-159.

  41. Morita H, Seidman J, Seidman E: Genetic causes of human heart failure. J Clin Invest 2005; 115: 518-526.

  42. Liew CC, Dzau VJ: Molecular genetics and genomics of heart failure. Nar Rev Genet 2004; 5: 811-825.

  43. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, Jogia D, et al: Defects in nuclear structure and function promote dilated cardiomyopathy in laminin A/C-deficient mice. J Clin Invest 2004; 113: 357-369.

  44. Pasotti M, Repetto A, Tavazzi L, Arbustini E: Genetic predisposition to heart failure. Med Clin N Am 2004; 88: 1173-1192.




2020     |     www.medigraphic.com